We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NTR:TSXNutrien Ltd. Analysis

Data as of 2026-08-30 - not real-time

CA$102.28

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Nutrien Ltd. is priced at CAD 102.28, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has gained 8.5%. Momentum indicators put RSI at 63.2 (approaching overbought) with MACD reading bullish. Recent trading has carved out support near CAD 89.50 and resistance around CAD 105.23.
Multiples put this in fair territory at a P/E of 15.0. Sell-side targets cluster 5.6% above the current quote. Revenue is growing at 4.0% on a 8.7% profit margin. The 3.05% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 4 — moderate. With 30-day volatility of 27.5%, a beta of -0.18 and a maximum drawdown of 24.9%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 5 out of 10.

Top Market Events

Nutrien Ltd. NTR is benefiting from favorable demand for crop nutrients, ongoing cost-reduction initiatives, strategic...Nutrien stock has delivered a 44.5% total return over the past five years, and the current Discounted Cash Flow DCF...Nutrien’s mixed quarter and updated outlook Nutrien TSX:NTR reported second quarter sales that were higher than...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • Trading above the 200-day average of 94.49
  • MACD momentum is positive
  • 30-day price change of +8.5%

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Trading above the 200-day average of 94.49
  • Analyst targets imply +5.6% versus the current price
  • MACD momentum is positive

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Analyst targets imply +5.6% versus the current price
  • P/E ratio of 15.0
  • Dividend yield of 3.05%

Key Metrics & Analysis

Financial Health

Revenue Growth4.00%
Profit Margin8.72%
P/E Ratio15.0
ROE9.44%
ROA4.31%
Debt/Equity49.07
P/B Ratio1.4
Op. Cash FlowCA$4.2B
Free Cash FlowCA$1.6B

Technical Analysis

TrendNeutral
RSI63.2
SupportCA$89.50
ResistanceCA$105.23
MA 20CA$96.94
MA 50CA$94.39
MA 200CA$94.49
MACDBullish
VolumeDecreasing
Fear & Greed Index95.66

Valuation

Fair ValueCA$26.42
Target PriceCA$108.02
Upside/Downside5.62%
GradeFair
TypeValue
Dividend Yield3.05%

Risk Assessment

Beta-0.18
Volatility27.51%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.